BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25341890)

  • 1. Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failure.
    Galindo CL; Kasasbeh E; Murphy A; Ryzhov S; Lenihan S; Ahmad FA; Williams P; Nunnally A; Adcock J; Song Y; Harrell FE; Tran TL; Parry TJ; Iaci J; Ganguly A; Feoktistov I; Stephenson MK; Caggiano AO; Sawyer DB; Cleator JH
    J Am Heart Assoc; 2014 Oct; 3(5):e000773. PubMed ID: 25341890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarction.
    Hill MF; Patel AV; Murphy A; Smith HM; Galindo CL; Pentassuglia L; Peng X; Lenneman CG; Odiete O; Friedman DB; Kronenberg MW; Zheng S; Zhao Z; Song Y; Harrell FE; Srinivas M; Ganguly A; Iaci J; Parry TJ; Caggiano AO; Sawyer DB
    PLoS One; 2013; 8(2):e55741. PubMed ID: 23437060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble transforming growth factor-beta1 receptor II might inhibit transforming growth factor-beta-induced myofibroblast differentiation and improve ischemic cardiac function after myocardial infarction in rats.
    Lian R; Chen Y; Xu Z; Zhang X
    Coron Artery Dis; 2010 Sep; 21(6):369-77. PubMed ID: 20613497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarction.
    Parry TJ; Ganguly A; Troy EL; Luis Guerrero J; Iaci JF; Srinivas M; Vecchione AM; Button DC; Hackett CS; Zolty R; Sawyer DB; Caggiano AO
    Eur J Pharmacol; 2017 Feb; 796():76-89. PubMed ID: 27993643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
    Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Neuregulin-1β Treatment Mitigates the Progression of Postmyocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus by Suppressing Myocardial Apoptosis, Fibrosis, and Key Oxidant-Producing Enzymes.
    Gupte M; Lal H; Ahmad F; Sawyer DB; Hill MF
    J Card Fail; 2017 Dec; 23(12):887-899. PubMed ID: 28870731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qiliqiangxin improves cardiac function and attenuates cardiac remodeling in rats with experimental myocardial infarction.
    Wang J; Zhou J; Ding X; Zhu L; Jiang K; Fu M; Wang S; Hu K; Ge J
    Int J Clin Exp Pathol; 2015; 8(6):6596-606. PubMed ID: 26261541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.
    Valiente-Alandi I; Potter SJ; Salvador AM; Schafer AE; Schips T; Carrillo-Salinas F; Gibson AM; Nieman ML; Perkins C; Sargent MA; Huo J; Lorenz JN; DeFalco T; Molkentin JD; Alcaide P; Blaxall BC
    Circulation; 2018 Sep; 138(12):1236-1252. PubMed ID: 29653926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.
    Yin M; van der Horst IC; van Melle JP; Qian C; van Gilst WH; Silljé HH; de Boer RA
    Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H459-68. PubMed ID: 21572014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 1 diabetes mellitus abrogates compensatory augmentation of myocardial neuregulin-1β/ErbB in response to myocardial infarction resulting in worsening heart failure.
    Odiete O; Konik EA; Sawyer DB; Hill MF
    Cardiovasc Diabetol; 2013 Mar; 12():52. PubMed ID: 23530877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure.
    Morine KJ; Qiao X; York S; Natov PS; Paruchuri V; Zhang Y; Aronovitz MJ; Karas RH; Kapur NK
    Circulation; 2018 Jul; 138(5):513-526. PubMed ID: 29487140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Human ADAMTS13 Treatment Improves Myocardial Remodeling and Functionality After Pressure Overload Injury in Mice.
    Witsch T; Martinod K; Sorvillo N; Portier I; De Meyer SF; Wagner DD
    J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling.
    Purcell BP; Barlow SC; Perreault PE; Freeburg L; Doviak H; Jacobs J; Hoenes A; Zellars KN; Khakoo AY; Lee T; Burdick JA; Spinale FG
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H814-H825. PubMed ID: 29979624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.
    Liu YH; D'Ambrosio M; Liao TD; Peng H; Rhaleb NE; Sharma U; André S; Gabius HJ; Carretero OA
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H404-12. PubMed ID: 19098114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boron improves cardiac contractility and fibrotic remodeling following myocardial infarction injury.
    Bouchareb R; Katz M; Saadallah N; Sassi Y; Ali S; Lebeche D
    Sci Rep; 2020 Oct; 10(1):17138. PubMed ID: 33051505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure.
    Milliez P; Messaoudi S; Nehme J; Rodriguez C; Samuel JL; Delcayre C
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H435-41. PubMed ID: 19074674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of neuregulin-1 on cardiac glucose metabolism in rats with experimental myocardial infarction].
    Wang JF; Li FH; Shen DL; Song Y; Wang YY; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Sep; 49(9):912-919. PubMed ID: 34530600
    [No Abstract]   [Full Text] [Related]  

  • 18. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
    Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
    Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTRP3 attenuates post-infarct cardiac fibrosis by targeting Smad3 activation and inhibiting myofibroblast differentiation.
    Wu D; Lei H; Wang JY; Zhang CL; Feng H; Fu FY; Li L; Wu LL
    J Mol Med (Berl); 2015 Dec; 93(12):1311-25. PubMed ID: 26138247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction.
    de Kleijn DPV; Chong SY; Wang X; Yatim SMJM; Fairhurst AM; Vernooij F; Zharkova O; Chan MY; Foo RSY; Timmers L; Lam CSP; Wang JW
    Cardiovasc Res; 2019 Oct; 115(12):1791-1803. PubMed ID: 30830156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.